Results 1 to 10 of about 29,210 (297)

Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma [PDF]

CPT: Pharmacometrics & Systems Pharmacology
Efficacy and safety of ibrutinib 560 mg once daily or placebo combined with bendamustine and rituximab (BR) were assessed in patients with mantle cell lymphoma in a randomized phase 3 study (SHINE).
Per Olsson Gisleskog, Belén Valenzuela, Nicoline Treijtel, Sanjay Deshpande, Todd Henninger, Juan José Perez‐Ruixo   +5 more
doaj   +3 more sources

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [PDF]

New England Journal of Medicine, 2013
John C Byrd, Ian W Flinn, Jan A Burger
exaly   +3 more sources

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK [PDF]

Proceedings of the National Academy of Sciences of the United States of America, 2015
Idit Sagiv-Barfi, Ronald Levy
exaly   +2 more sources

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells

Proceedings of the National Academy of Sciences of the United States of America, 2014
Rajarshi Guha, Ryan M Young, Adam Yasgar
exaly   +2 more sources

The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae

Frontiers in Pharmacology, 2021
Ibrutinib is an orally bioavailable, irreversible selective Bruton’s tyrosine kinase inhibitor that has demonstrated impressive therapeutic effects in patients with B cell malignancies.
Kun Wang, Qiushi Xu, Hanbing Zhong
doaj   +1 more source

Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy

Haematologica, 2021
Ibrutinib is highly active and produces long-term responses in patients with Waldenström macroglobulinemia (WM), but acquired resistance can occur with prolonged treatment.
Joshua N. Gustine, Shayna Sarosiek, Catherine A. Flynn, Kirsten Meid, Carly Leventoff, Timothy White, Maria Luisa Guerrera, Lian Xu, Amanda Kofides, Nicholas Tsakmaklis, Manit Munshi, Maria Demos, Christopher J. Patterson, Xia Liu, Guang Yang, Zachary R. Hunter, Andrew R. Branagan, Steven P. Treon, Jorge J. Castillo   +18 more
doaj   +1 more source

Simultaneous Determination of Orelabrutinib, Zanubrutinib, Ibrutinib and Its Active Metabolite in Human Plasma Using LC-MS/MS

Molecules, 2023
Ibrutinib, orelabrutinib, and zanubrutinib are all Bruton’s tyrosine kinase inhibitors, which have greatly improved the treatment of B-cell malignancies. In this study, an LC-MS/MS method was developed and validated for the determination of orelabrutinib,
Lu-Ning Sun, Yang Zhao, Zhou-Yi Qian, Xiang-Long Chen, Hong Ma, Yu-Jiao Guo, Hao Shen, Yong-Qing Wang   +7 more
doaj   +1 more source

Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry

Pathology and Oncology Research, 2022
Background: Ibrutinib is widely known as an effective and well-tolerated therapeutical choice of the chronic lymphocytic leukaemia (CLL). However, acquired resistance may occur during the treatment, causing relapse.
Ferenc Takács, Ferenc Takács, Lili Kotmayer, Ágnes Czeti, Gábor Szalóki, Tamás László, Gábor Mikala, Ágnes Márk, András Masszi, Péter Farkas, Márk Plander, Júlia Weisinger, Judit Demeter, Sándor Fekete, László Szerafin, Beáta Margit Deák, Erika Szaleczky, Adrienn Sulák, Zita Borbényi, Gábor Barna   +19 more
doaj   +1 more source

Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study

Cancer Medicine, 2022
Background Ibrutinib has revolutionized the treatment of mantle cell lymphoma (MCL). Both ibrutinib monotherapy and ibrutinib‐based combination therapy are important salvage options for patients with relapsed/refractory (R/R) MCL. The real‐world efficacy
Yuchen Zhang, Panpan Liu, Jun Cai, Hongmei Jing, Liqun Zou, Huiqiang Huang, Yuanbin Wu, Wenyu Li, Liye Zhong, Xueli Jin, Xu Ye, Ru Feng, Huilai Zhang, Liling Zhang, Lie Lin, Xiuhua Sun, Yuyang Tian, Zhongjun Xia, Zhiming Li, He Huang, Yi Xia, Qingqing Cai   +21 more
doaj   +1 more source

Ibrutinib-related uveitis: A case series

American Journal of Ophthalmology Case Reports, 2022
Purpose: Four cases of ibrutinib-related uveitis are presented, which are to the best of our knowledge the first in the literature. Possible mechanisms of ibrutinib-mediated uveitis are explored.
Zelia K. Chiu, Jonathan KS. Goh, Cecilia Ling, Ming-Lee Lin, Anthony J. Hall   +4 more
doaj   +1 more source